Work

Abstract LB-64: GDC-0032, a beta isoform-sparing PI3K inhibitor: Results of a first-in-human phase Ia dose escalation study.

Year: 2013

Type: conference-abstract

Source: Cancer Research

DOI: 10.1158/1538-7445.am2013-lb-64

Authors: Dejan Juric, Ian Krop, Ramesh K. Ramanathan, Jim Xiao, Sandra Sanabria, Timothy R. Wilson, YounJeong Choi, Hema Parmar, Jerry Hsu, Jose Baselga, Daniel D. Von Hoff

Institutions: Massachusetts General Hospital, Dana-Farber Cancer Institute, Translational Genomics Research Institute, Genentech

Language: English

Topic: PI3K/AKT/mTOR signaling in cancer

Subfield: Molecular Biology

Field: Biochemistry, Genetics and Molecular Biology

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2009400945

Cites:

Cited by: 43

Related to: 10